ANTOXERENE identifies small molecule compounds to target pathways of aging

Antoxerene performs pipeline testing for small molecule drugs that target protein-drug and protein-protein interactions. The platform is based on a patent-pending production technology, which enables manufacturing of impossible to express protein targets in biologically active form, at scale.

Learn more

Neurodegenerative disease



High-throughput drug screens are an essential component of any medical research program. With the creation of a subsidiary to focus on such screens, Ichor is emphasizing its determination to make pivotal contributions in the development of a broad range of therapies to repair the damage of aging - real rejuvenation biotechnology.

Aubrey de Grey, Ph.D.

Latest News from ANTOXERENE